Real‐world persistence of erenumab for preventive treatment of chronic and episodic migraine: Retrospective real‐world study

Gladstone, Jonathan P.; Chhibber, Sameer; Minhas, Jagdeep K; Neish, Calum S.; Power, G Sarah; Lan, Zhiyi; Rochdi, Driss; Lanthier-Martel, Jessica; Bastien, Natacha

doi:10.1111/head.14218

Cited by 11 publications

(17 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…respectively. Recently published real-world data on the use of these substances in episodic migraine [12] as well as in a di cult-to-treat considered patient group experiencing chronic migraine [13] and medication-overuse-headache (MOH) [14,15] a rmed their potential. Literature suggests that CGRP-mAbs, along with their favorable safety and tolerability pro le, might be superior compared to previously established preventive migraine therapies such as beta-blockers, antiepileptics, calcium-channel blockers, or tricyclic antidepressants: A meta-analysis comparing topiramate to CGRP-antibodies in EM con rmed the excellent tolerability of monoclonal antibodies despite a comparable reduction of migraine days.…”

Section: Introductionmentioning

confidence: 99%

Monoclonal Antibodies Against CGRP (R): Non-responders and Switchers: Real World Data from a Large Case Series

Kaltseis

Filippi

Frank

et al. 2022

Preprint

View full text Add to dashboard Cite

ObjectiveAssessement of the responder and non-responder rate to consecutive monoclonal CGRP-antibody (CGRP-mAb) treatment, the presence of side effects, analysis of predictors of response and loss of efficacy evaluation over time. Methods We conducted a retrospective analysis including 171 patients with episodic (EM) or chronic migraine (CM), who received one, two or three different CGRP-(R)-mAbs. Non-response was defined as ≤50% reduction of monthly migraine days (MMDs) in EM and ≤ 30% reduction of MMDs in CM after 3 months of treatment. Results71.9% responded to the first mAb. Side effects led to treatment discontinuation in 5.3%. Of the 26 patients who did not respond to the first mAb or experienced a loss of efficacy over time, 11 (42.3%) responded to the second and two of 7 to the third monoclonal antibody. Poor response to therapy was associated with a higher monthly headache frequency (p = 0.042), pre-existing psychiatric disorder (p = 0.032), and a higher number of prior preventive migraine therapies (p = 0.022).ConclusionOur findings support mAb-class switch in non-responders or in patients experiencing a loss of efficacy. The use of a third CGRP-mAb could be beneficial for some patients. Early use of CGRP-mAbs in the prevention of migraine might help to avert chronification of migraine and treatment-refractory patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Monoclonal Antibodies Against CGRP (R): Non-responders and Switchers: Real World Data from a Large Case Series

Kaltseis

Filippi

Frank

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…All but two pharmacoepidemiologic studies included only Erenumab which was marketed first [32][33][34][35]37,38]. All studies bear the risk of bias, as they were supported by pharmaceutical companies.…”

Section: Discussionmentioning

confidence: 99%

“…Three studies examined the adherence or persistence. [34,35,39] The adherence to anti-CGRP-mAbs was higher ( 0.8), than to oral prophylactics; but still not at optimum [35]. In the Novartis Go Program [34] offering advice, injection training and Erenumab free of charge until the individual insurance was willing/able to pay for Erenumab, the persistence of treatment was 71 % at 360 days and 63 % at 450 days which is better than under oral preventives [1].…”

Section: Adherence and Persistencementioning

confidence: 99%

“…An exact breakdown of the search results can be seen in Figure 1. We classified these articles into pharmacoepidemiologic studies (n=8) [32][33][34][35][36][37][38][39], clinicbased studies (n=63) , case reports (n=30) and other articles (n=3) [133][134][135]. Seventy-three articles were retrospective and 31 prospective .…”

Section: Study Characteristicsmentioning

confidence: 99%

“…[34,35,39] The adherence to anti-CGRP-mAbs was higher ( 0.8), than to oral prophylactics; but still not at optimum [35]. In the Novartis Go Program [34] offering advice, injection training and Erenumab free of charge until the individual insurance was willing/able to pay for Erenumab, the persistence of treatment was 71 % at 360 days and 63 % at 450 days which is better than under oral preventives [1]. Varnado et al [39] found a higher main persistence under anti-CGRP-mAbs, than under standard prophylactics, and a significantly higher adherence at six and 12 months (medication possession rate 58 % vs. 37 %, proportion of days covered 55 % vs. 35 %).…”

Section: Adherence and Persistencementioning

confidence: 99%

See 2 more Smart Citations

Monoclonal Antibodies Against Calcitonin Gene-related Peptide for Migraine Prophylaxis: A Systematic Review of Real-world Data

Pavelic¹,

Wöber²,

Riederer³

et al. 2022

Preprint

View full text Add to dashboard Cite

Objective: To perform a systematic review of real-world outcomes for anti-CGRP-mAbs. Methods: Following the PRISMA guidelines, we searched PubMed for real-world data of Erenumab, Galcanezumab, Fremanezumab, or Eptinezumab in patients with migraine. Results: We identified 104 publications (73 retrospective), comprising 8 pharmaco-epidemiologic and 63 clinic-based studies, 30 case reports and 3 other articles. None of the clinic-based studies provided follow-up data over more than one year in more than 200 patients. Findings suggest reductions in health insurance claims and days with sick-leave as well as better treatment adherence with anti-CGRP-mAbss. Effectiveness, reported in 59 clinic-based studies, was comparable to randomized controlled trials. A treatment pause was associated with an increase in migraine frequency and switching to another antibody resulted in a better response in some of the patients. Adverse events and safety issues were addressed in 70 papers including 22 single case reports. Conclusion: Real-world data on anti-CGRP-mAbs are limited by retrospective data collection, small patient numbers and short follow-up periods. The majority of papers seem to support good effectiveness and tolerability of anti-CGRP-mAbs in the real-world setting. There is an unmet need for large prospective real-world studies providing long-term follow-up of patients treated with anti-CGRP-mAbs.

show abstract

Utilization, Expenditure, and Treatment Patterns Associated With Calcitonin Gene-Related Peptide Monoclonal Antibodies Reimbursed Subject to a Managed Access Protocol in Ireland

Smith,

Finnigan,

Clarke

et al. 2024

Value in Health

View full text Add to dashboard Cite

Real‐world persistence of erenumab for preventive treatment of chronic and episodic migraine: Retrospective real‐world study

Abstract: This is an open access article under the terms of the Creat ive Commo ns Attri butio n NonCo mmercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

Cited by 11 publications

References 25 publications

Monoclonal Antibodies Against CGRP (R): Non-responders and Switchers: Real World Data from a Large Case Series

Monoclonal Antibodies Against CGRP (R): Non-responders and Switchers: Real World Data from a Large Case Series

Monoclonal Antibodies Against Calcitonin Gene-related Peptide for Migraine Prophylaxis: A Systematic Review of Real-world Data

Utilization, Expenditure, and Treatment Patterns Associated With Calcitonin Gene-Related Peptide Monoclonal Antibodies Reimbursed Subject to a Managed Access Protocol in Ireland

Contact Info

Product

Resources

About